Evidence map›Paper›PMID 40494869›Full record

ArticleCell death & disease2025

Genes driving three-dimensional growth of immortalized cells and cancer.

Mukta Basu, Jin-Fen Xiao, Saravana Kumar Kailasam Mani, Fangyuan Qu, Yongqi Lin, Jason Duex, Huihui Ye, Vanessa Neang, Dan Theodorescu

Abstract read
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mukta Basu *Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Jin-Fen Xiao *Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Saravana Kumar Kailasam ManiDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-0407-2314
Fangyuan QuDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Yongqi LinDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Jason DuexDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Huihui YeDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Vanessa NeangDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Dan TheodorescuDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. theodorescu@arizona.edu.ORCID http://orcid.org/0000-0002-8708-8206

Funding

Regulation and Targeting of CD24 in Bladder CancerR01CA075115 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI THEODORESCU, DAN · 2003 to 2024
$7.0M
MECHANISMS OF BLADDER CANCER INVANSIONR29CA075115 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI THEODORESCU, DAN · 1997 to 2001
$217k
NCI NIH HHS R01 CA075115NCI NIH HHS R29 CA075115U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA075115
6 · The paper itself

Abstract

Unchecked growth in three-dimensions (3D) in culture is a key feature of immortalized cells on the path to malignant transformation and hence a potential target phenotype for prevention. Also, expression of genes driving this process, but not that of 2D growth, would likely be more specific to cancer development and their inhibition would be less toxic to normal cells, many of which can grow in 2D but rarely in 3D culture. To define such genes, we compared CRISPR depletion screens performed in HBLAK, a spontaneously immortalized, non-tumorigenic human urothelial cell line, grown in 2D to those in 3D. Using the CRISPR Bassik DTKP (drug target kinase phosphatase) deletion library targeting 2,333 genes, we identified 85 genes which were specifically lost in 3D cultures. Prioritizing hits to those associated with bladder cancer in patients provided us with a set of 11 genes. Only one gene, MAPK1 remained relevant if a human pan-cancer criteria was applied. Single gene in vitro validation confirmed that MAPK1 inhibition was specific to 3D growth. We also found that MAPK1 depletion led to significant growth reductions in human tumor xenografts in vivo. Inhibition of MAPK1 by Ulixertinib, an orally active MAPK1 inhibitor, led to human bladder cancer growth inhibition in both 3D in vitro and in vivo models. In summary, screening for genes specifically driving 3D growth in immortalized cells may provide targets for both prevention and early therapy in bladder and other cancers while potentially limiting therapeutic toxicity.

Indexed as

Urinary Bladder NeoplasmsAnimalsCell Line, TumorCell ProliferationCell Transformation, NeoplasticCRISPR-Cas SystemsHumansMiceMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 1

Identifiers

PMID40494869
PMCPMC12152191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.